Ikena Oncology, Inc. Common Stock
IKNA Real Time Price USDRecent trades of IKNA by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by IKNA's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Indole ahr inhibitors and uses thereof Sep. 03, 2024
-
Patent Title: Aryl hydrocarbon receptor (ahr) agonists and uses thereof Jul. 09, 2024
-
Patent Title: Tead inhibitors and uses thereof Mar. 12, 2024
-
Patent Title: Mek inhibitors and uses thereof Jan. 23, 2024
-
Patent Title: Tead inhibitors and uses thereof Sep. 19, 2023
-
Patent Title: Aryl hydrocarbon receptor (ahr) agonists and uses thereof Mar. 21, 2023
-
Patent Title: Solid forms of (r)-n-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[ 1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1h-carbazol-3-amine maleate as aryl hydrocarbon receptor (ahr) inhibitors Feb. 28, 2023
-
Patent Title: Ahr inhibitors and uses thereof Jan. 17, 2023
-
Patent Title: Tead inhibitors and uses thereof Oct. 04, 2022
-
Patent Title: Indole ahr inhibitors and uses thereof Jun. 14, 2022
-
Patent Title: Tead inhibitors and uses thereof Mar. 15, 2022
-
Patent Title: Ahr inhibitors and uses thereof Jun. 30, 2020
-
Patent Title: Indole ahr inhibitors and uses thereof Jun. 23, 2020
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of IKNA in WallStreetBets Daily Discussion
Recent insights relating to IKNA
Recent picks made for IKNA stock on CNBC
ETFs with the largest estimated holdings in IKNA
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view IKNA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.